- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00402363
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
1 de dezembro de 2016 atualizado por: GlaxoSmithKline
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
663
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35215
- GSK Investigational Site
-
Huntsville, Alabama, Estados Unidos, 35801
- GSK Investigational Site
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- GSK Investigational Site
-
-
Arizona
-
Cottonwood, Arizona, Estados Unidos, 86326
- GSK Investigational Site
-
Mesa, Arizona, Estados Unidos, 85206
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85006
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85032
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85014
- GSK Investigational Site
-
Tucson, Arizona, Estados Unidos, 85724
- GSK Investigational Site
-
-
Arkansas
-
Fort Smith, Arkansas, Estados Unidos, 72901
- GSK Investigational Site
-
Hot Springs, Arkansas, Estados Unidos, 71913
- GSK Investigational Site
-
-
California
-
Alamada, California, Estados Unidos, 94501
- GSK Investigational Site
-
Bakersfield, California, Estados Unidos, 93301
- GSK Investigational Site
-
Bakersfield, California, Estados Unidos, 93308
- GSK Investigational Site
-
Beverly Hills, California, Estados Unidos, 90210
- GSK Investigational Site
-
Carmichael, California, Estados Unidos, 95608
- GSK Investigational Site
-
Fair Oaks, California, Estados Unidos, 95628
- GSK Investigational Site
-
Fountain Valley, California, Estados Unidos, 92708
- GSK Investigational Site
-
Loma Linda, California, Estados Unidos, 92354
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90073
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90048
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90033
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90211
- GSK Investigational Site
-
Merced, California, Estados Unidos, 95348
- GSK Investigational Site
-
Palm Springs, California, Estados Unidos, 92262
- GSK Investigational Site
-
Poway, California, Estados Unidos, 92064
- GSK Investigational Site
-
Redondo Beach, California, Estados Unidos, 90277
- GSK Investigational Site
-
Sacramento, California, Estados Unidos, 95819
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92123
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92120
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92161
- GSK Investigational Site
-
Vista, California, Estados Unidos, 92081
- GSK Investigational Site
-
Walnut Creek, California, Estados Unidos, 94598
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- GSK Investigational Site
-
Colorado Springs, Colorado, Estados Unidos, 80907
- GSK Investigational Site
-
Littleton, Colorado, Estados Unidos, 80120
- GSK Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06606
- GSK Investigational Site
-
Farmington, Connecticut, Estados Unidos, 06030
- GSK Investigational Site
-
Guilford, Connecticut, Estados Unidos, 06437
- GSK Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010
- GSK Investigational Site
-
Washington, District of Columbia, Estados Unidos, 20017
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- GSK Investigational Site
-
Bay Pines, Florida, Estados Unidos, 33744
- GSK Investigational Site
-
Daytona Beach, Florida, Estados Unidos, 32114
- GSK Investigational Site
-
Delray Beach, Florida, Estados Unidos, 33484
- GSK Investigational Site
-
Fort Meyers, Florida, Estados Unidos, 33919
- GSK Investigational Site
-
Gainesville, Florida, Estados Unidos, 32605
- GSK Investigational Site
-
Hudson, Florida, Estados Unidos, 34667
- GSK Investigational Site
-
Jacksonville, Florida, Estados Unidos, 32216
- GSK Investigational Site
-
Jacksonville, Florida, Estados Unidos, 32207
- GSK Investigational Site
-
Jupiter, Florida, Estados Unidos, 33458
- GSK Investigational Site
-
Kissimmee, Florida, Estados Unidos, 34741
- GSK Investigational Site
-
Largo, Florida, Estados Unidos, 33773
- GSK Investigational Site
-
Melbourne, Florida, Estados Unidos, 32901
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33136
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33137
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33176
- GSK Investigational Site
-
Ocala, Florida, Estados Unidos, 34471
- GSK Investigational Site
-
Orlando, Florida, Estados Unidos, 32803
- GSK Investigational Site
-
Ormond Beach, Florida, Estados Unidos, 32174
- GSK Investigational Site
-
Pensacola, Florida, Estados Unidos, 32514
- GSK Investigational Site
-
Pinellas Park, Florida, Estados Unidos, 33781
- GSK Investigational Site
-
Tampa, Florida, Estados Unidos, 33607
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- GSK Investigational Site
-
Atlanta, Georgia, Estados Unidos, 30322
- GSK Investigational Site
-
Atlanta, Georgia, Estados Unidos, 30328
- GSK Investigational Site
-
Decatur, Georgia, Estados Unidos, 30030
- GSK Investigational Site
-
Tucker, Georgia, Estados Unidos, 30084
- GSK Investigational Site
-
-
Illinois
-
Bannockburn, Illinois, Estados Unidos, 60015
- GSK Investigational Site
-
Gurnee, Illinois, Estados Unidos, 60031
- GSK Investigational Site
-
Normal, Illinois, Estados Unidos, 61761
- GSK Investigational Site
-
Peoria, Illinois, Estados Unidos, 61603
- GSK Investigational Site
-
-
Indiana
-
Elkhart, Indiana, Estados Unidos, 46514
- GSK Investigational Site
-
Indianapolis, Indiana, Estados Unidos, 46260
- GSK Investigational Site
-
La Porte, Indiana, Estados Unidos, 46350
- GSK Investigational Site
-
South Bend, Indiana, Estados Unidos, 46601
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66102
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40205
- GSK Investigational Site
-
Mount Sterling, Kentucky, Estados Unidos, 40353
- GSK Investigational Site
-
-
Louisiana
-
Covington, Louisiana, Estados Unidos, 70433
- GSK Investigational Site
-
Lacombe, Louisiana, Estados Unidos, 70445
- GSK Investigational Site
-
-
Maine
-
Auburn, Maine, Estados Unidos, 04210
- GSK Investigational Site
-
Biddeford, Maine, Estados Unidos, 04005
- GSK Investigational Site
-
Portland, Maine, Estados Unidos, 04106
- GSK Investigational Site
-
Scarborough, Maine, Estados Unidos, 04074
- GSK Investigational Site
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 20401
- GSK Investigational Site
-
-
Massachusetts
-
Ayer, Massachusetts, Estados Unidos, 01432
- GSK Investigational Site
-
Brookline, Massachusetts, Estados Unidos, 02446
- GSK Investigational Site
-
Worcester, Massachusetts, Estados Unidos, 01655
- GSK Investigational Site
-
-
Michigan
-
Alpena, Michigan, Estados Unidos, 49707
- GSK Investigational Site
-
Cadillac, Michigan, Estados Unidos, 49601
- GSK Investigational Site
-
Detroit, Michigan, Estados Unidos, 48201
- GSK Investigational Site
-
Kalamazoo, Michigan, Estados Unidos, 49048
- GSK Investigational Site
-
Lansing, Michigan, Estados Unidos, 48910
- GSK Investigational Site
-
-
Minnesota
-
Mineappolis, Minnesota, Estados Unidos, 55417
- GSK Investigational Site
-
Rochester Hills, Minnesota, Estados Unidos, 48307
- GSK Investigational Site
-
St Paul, Minnesota, Estados Unidos, 55102
- GSK Investigational Site
-
-
Mississippi
-
Gulfport, Mississippi, Estados Unidos, 39503
- GSK Investigational Site
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- GSK Investigational Site
-
Kalispell, Montana, Estados Unidos, 59901
- GSK Investigational Site
-
Missoula, Montana, Estados Unidos, 59802
- GSK Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962
- GSK Investigational Site
-
Summit, New Jersey, Estados Unidos, 07901
- GSK Investigational Site
-
Wayne, New Jersey, Estados Unidos, 07470
- GSK Investigational Site
-
-
New York
-
Babylon, New York, Estados Unidos, 11702
- GSK Investigational Site
-
Buffalo, New York, Estados Unidos, 14215
- GSK Investigational Site
-
Buffalo, New York, Estados Unidos, 14209
- GSK Investigational Site
-
Mineola, New York, Estados Unidos, 11501
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10032
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10025
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10021
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10029
- GSK Investigational Site
-
Troy, New York, Estados Unidos, 12180
- GSK Investigational Site
-
West Islip, New York, Estados Unidos, 11794
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- GSK Investigational Site
-
Charlotte, North Carolina, Estados Unidos, 28080
- GSK Investigational Site
-
Hickory, North Carolina, Estados Unidos, 28601
- GSK Investigational Site
-
Statesville, North Carolina, Estados Unidos, 28625
- GSK Investigational Site
-
-
North Dakota
-
Grand Forks, North Dakota, Estados Unidos, 58201
- GSK Investigational Site
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- GSK Investigational Site
-
Bryan, Ohio, Estados Unidos, 43506
- GSK Investigational Site
-
Cincinnati, Ohio, Estados Unidos, 45219
- GSK Investigational Site
-
Cleveland, Ohio, Estados Unidos, 44106
- GSK Investigational Site
-
Fairview Park, Ohio, Estados Unidos, 44126
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73103
- GSK Investigational Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- GSK Investigational Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73109
- GSK Investigational Site
-
-
Oregon
-
Corvalis, Oregon, Estados Unidos, 97330
- GSK Investigational Site
-
Hillsboro, Oregon, Estados Unidos, 97123-4117
- GSK Investigational Site
-
Portland, Oregon, Estados Unidos, 97220
- GSK Investigational Site
-
Portland, Oregon, Estados Unidos, 97223
- GSK Investigational Site
-
-
Pennsylvania
-
Beaver, Pennsylvania, Estados Unidos, 15009
- GSK Investigational Site
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- GSK Investigational Site
-
Hershey, Pennsylvania, Estados Unidos, 17033
- GSK Investigational Site
-
Langhorne, Pennsylvania, Estados Unidos, 19047
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Estados Unidos, 19102
- GSK Investigational Site
-
Ridley Park, Pennsylvania, Estados Unidos, 19078
- GSK Investigational Site
-
West Chester, Pennsylvania, Estados Unidos, 19380
- GSK Investigational Site
-
Wynnewood, Pennsylvania, Estados Unidos, 19096
- GSK Investigational Site
-
Wyomissing, Pennsylvania, Estados Unidos, 19610
- GSK Investigational Site
-
-
Rhode Island
-
Cranston, Rhode Island, Estados Unidos, 02920
- GSK Investigational Site
-
Pawtucket, Rhode Island, Estados Unidos, 02860
- GSK Investigational Site
-
Westerly, Rhode Island, Estados Unidos, 02891
- GSK Investigational Site
-
-
South Carolina
-
Greer, South Carolina, Estados Unidos, 29651
- GSK Investigational Site
-
Spartanburg, South Carolina, Estados Unidos, 29302
- GSK Investigational Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- GSK Investigational Site
-
-
Tennessee
-
Jackson, Tennessee, Estados Unidos, 38301
- GSK Investigational Site
-
Memphis, Tennessee, Estados Unidos, 38120
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- GSK Investigational Site
-
Beaumont, Texas, Estados Unidos, 77702
- GSK Investigational Site
-
Corpus Christi, Texas, Estados Unidos, 78404
- GSK Investigational Site
-
Dallas, Texas, Estados Unidos, 75230
- GSK Investigational Site
-
Dallas, Texas, Estados Unidos, 75231
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77074
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77090
- GSK Investigational Site
-
Humble, Texas, Estados Unidos, 77338
- GSK Investigational Site
-
Lubbock, Texas, Estados Unidos, 79410
- GSK Investigational Site
-
McKinney, Texas, Estados Unidos, 75069
- GSK Investigational Site
-
Odessa, Texas, Estados Unidos, 79761
- GSK Investigational Site
-
Odessa, Texas, Estados Unidos, 79764
- GSK Investigational Site
-
Orange, Texas, Estados Unidos, 77630
- GSK Investigational Site
-
Tyler, Texas, Estados Unidos, 75701
- GSK Investigational Site
-
Waco, Texas, Estados Unidos, 76712
- GSK Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84124
- GSK Investigational Site
-
-
Virginia
-
Arlington, Virginia, Estados Unidos, 22204
- GSK Investigational Site
-
Chesapeake, Virginia, Estados Unidos, 23510
- GSK Investigational Site
-
Galax, Virginia, Estados Unidos, 24333
- GSK Investigational Site
-
Richlands, Virginia, Estados Unidos, 24641
- GSK Investigational Site
-
Richmond, Virginia, Estados Unidos, 23249
- GSK Investigational Site
-
Richmond, Virginia, Estados Unidos, 23294
- GSK Investigational Site
-
Springfield, Virginia, Estados Unidos, 22151
- GSK Investigational Site
-
-
Washington
-
Burien, Washington, Estados Unidos, 98166
- GSK Investigational Site
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- GSK Investigational Site
-
-
Wisconsin
-
Beloit, Wisconsin, Estados Unidos, 53511
- GSK Investigational Site
-
Madison, Wisconsin, Estados Unidos, 53792
- GSK Investigational Site
-
Marshfield, Wisconsin, Estados Unidos, 54449
- GSK Investigational Site
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- GSK Investigational Site
-
Wausau, Wisconsin, Estados Unidos, 54401
- GSK Investigational Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Men and women age 18 years or older
- History of symptomatic atrial fibrillation (either paroxysmal or persistent)
- Provide written informed consent and authorization for protected health information disclosure
Exclusion Criteria:
- Permanent (chronic) atrial fibrillation
- Antiarrhythmic drug therapy which cannot be stopped
- Use of amiodarone with prior 6 months
- History of unsuccessful cardioversion
- History of certain cardiovascular conditions or cardiac surgery within prior 6 months
- History of stroke within prior 6 months
- Implanted cardio-defibrillator
- Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except non-melanoma skin cancer)
- Poorly controlled diabetes
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
|
|
Experimental: omega-3-acid ethyl esters
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter
Prazo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF /Flutter was defined as AF/Flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Persistent AF and in Both AF Subgroups Combined With an Event of Documented Symptomatic AF/Flutter
Prazo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal AF or Persistent AF With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
Prazo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
Prazo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
Prazo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
Prazo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
Prazo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
Prazo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
Prazo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
Prazo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
Prazo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
Prazo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Annualized Number of AF/Flutter Rescue Episodes During the Treatment Period
Prazo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Rescue was defined as any pharmacological/electrical/surgical intervention for the termination/prevention of AF/flutter with a maximum of one rescue episode counted per day.
Note: all annualized values were calculated by counting the number of rescue episodes, dividing by the number of days on treatment, then multiplying that number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF/Flutter Recurrences During the Treatment Period
Prazo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF/flutter recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF Recurrences During the Treatment Period
Prazo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2363-72. doi: 10.1001/jama.2010.1735. Epub 2010 Nov 15.
- Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009 Aug;158(2):163-169.e1-3. doi: 10.1016/j.ahj.2009.05.024.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de novembro de 2006
Conclusão Primária (Real)
1 de janeiro de 2010
Conclusão do estudo (Real)
1 de janeiro de 2010
Datas de inscrição no estudo
Enviado pela primeira vez
20 de novembro de 2006
Enviado pela primeira vez que atendeu aos critérios de CQ
20 de novembro de 2006
Primeira postagem (Estimativa)
22 de novembro de 2006
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
30 de janeiro de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
1 de dezembro de 2016
Última verificação
1 de dezembro de 2016
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- OM8 Afib
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Sim
Descrição do plano IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Dados/documentos do estudo
-
Formulário de Consentimento Informado
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de dados de participantes individuais
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Relato de Caso Anotado
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Especificação do conjunto de dados
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudo
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Plano de Análise Estatística
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Relatório de Estudo Clínico
Identificador de informação: OM8 AfibComentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .